

- Altekruse S, Kosary C, Krapcho M, et al. *SEER Cancer Statistics Review, 1975-2007*. Bethesda, MD: National Cancer Institute; 2010.
- Provocative Questions: Identifying Problems to Drive Progress Against Cancer. National Cancer Institute Web site. <http://provocativequestions.nci.nih.gov/>.
- Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. *CA Cancer J Clin* 2012;62:220-241.
- Cancer survivors: living longer, and now, better. *Lancet* 2004;364:2153-2154.
- Travis LB. Therapy-associated solid tumors. *Acta Oncol* 2002;41:323-333.
- Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship—genetic susceptibility and second primary cancers: research strategies and recommendations. *J Natl Cancer Inst* 2006;98:15-25.
- Curtis RE, Ron E, Hankey BF, Hoover RN. New malignancies following breast cancer. In: Curtis RE, Freedman DM, Ron E, et al., eds. *New Malignancies among Cancer Survivors: SEER Cancer Registries, 1973-2000*. NIH Publ No 05-0532. Bethesda, MD: National Cancer Institute; 2006: 181-206.
- Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. *J Clin Oncol* 2002;20:2101-2108.
- Travis LB, Boice JD Jr, Allan JM, et al. Report No. 170—Second Primary Cancers and Cardiovascular Disease after Radiation Therapy. National Council on Radiation Protection & Measurements Web site. <http://www.ncrppublications.org/Reports/170>.
- Travis LB, Ng AK, Allan JM, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. *J Natl Cancer Inst* 2012;104: 357-370.
- Solomon BM, Rabe KG, Slager SL, et al. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. *J Clin Oncol* 2013;31:930-937.
- Vardy J, Agar M. Outcomes in cancer survivors who develop second malignant neoplasms [podcast]. <http://jco.ascopubs.org/site/podcasts/index.xhtml>.
- Milano MT, Li H, Constone LS, et al. Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients. *Cancer* 2011;117:5538-5547.
- Youn P, Li H, Milano MT, et al. Long-term survival among Hodgkin's lymphoma patients with gastrointestinal cancer: a population-based study. *Ann Oncol* 2013;24:202-208.
- Milano MT, Li H, Gail MH, et al. Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. *J Clin Oncol* 2010;28:5088-5096.
- Schäirer C, Hisada M, Chen BE, et al. Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. *J Natl Cancer Inst* 2007;99:1248-1256.
- Armstrong GT, Liu W, Leisenring W, et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2011;29:3056-3064.
- Sakoda LC, Jorgenson E, Witte JS. Turning of COGS moves forward findings for hormonally mediated cancers. *Nat Genet* 2013;45:345-348.
- Wanebo CK, Johnson KG, Sato K, et al. Breast cancer after exposure to the atomic bombings of Hiroshima and Nagasaki. *N Engl J Med* 1968;279: 667-671.
- Wanebo CK, Johnson KG, Sato K, et al. Lung cancer following atomic radiation. *Am Rev Respir Dis* 1968;98:778-787.
- Wood JW, Tamagaki H, Nerishi S, et al. Thyroid carcinoma in atomic bomb survivors Hiroshima and Nagasaki. *Am J Epidemiol* 1969;89:4-14.
- Thompson DE, Mabuchi K, Ron E, et al. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. *Radiat Res* 1994;137:S17-S67.
- Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. *Radiat Res* 1994;137:S68-S97.
- Dropkin C. Reanalysis of cancer mortality in Japanese A-bomb survivors exposed to low doses of radiation: bootstrap and simulation methods. *Environ Health* 2009;8:56.
- Richardson D, Sugiyama H, Nishi N, et al. Ionizing radiation and leukemia mortality among Japanese atomic bomb survivors, 1950-2000. *Radiat Res* 2009;172:368-382.
- Howe GR, McLaughlin J. Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with breast cancer mortality in the atomic bomb survivors study. *Radiat Res* 1996;145:694-707.
- Little MP, Boice JD Jr. Comparison of breast cancer incidence in the Massachusetts tuberculosis fluoroscopy cohort and in the Japanese atomic bomb survivors. *Radiat Res* 1999;151:218-224.
- Little MP, Weiss HA, Boice JD Jr, et al. Risks of leukemia in Japanese atomic bomb survivors, in women treated for cervical cancer, and in patients treated for ankylosing spondylitis. *Radiat Res* 1999;152:280-292.
- Doody MM, Lonstein JE, Stovall M, et al. Breast cancer mortality after diagnostic radiography: findings from the U.S. Scoliosis Cohort Study. *Spine (Phila Pa 1976)* 2000;25:2052-2063.
- Adams MJ, Dozier A, Shore RE, et al. Breast cancer risk 55+ years after irradiation for an enlarged thymus and its implications for early childhood medical irradiation today. *Cancer Epidemiol Biomarkers Prev* 2010;19:48-58.
- Boice JD Jr, Preston D, Davis FG, et al. Frequent chest X-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. *Radiat Res* 1991;125:214-222.
- Preston DL, Mattsson A, Holmberg E, et al. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. *Radiat Res* 2002;158:220-235.
- Curtis RE, Boice JD Jr, Stovall M, et al. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. *J Natl Cancer Inst* 1994;86:1315-1324.
- Boice JD Jr, Bletner M, Kleinerman RA, et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. *J Natl Cancer Inst* 1987;79:1295-1311.
- Mole RH. Ionizing radiation as a carcinogen: practical questions and academic pursuits. The Silvanus Thompson Memorial Lecture delivered at The British Institute of Radiology on April 18, 1974. *Br J Radiol* 1975;48:157-169.
- Gorlin RJ. Nevroid basal-cell carcinoma syndrome. *Medicine* 1987;66: 98-113.
- Chompret A. The Li-Fraumeni syndrome. *Biochimie* 2002;84:75-82.
- Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. *Orphanet J Rare Dis* 2009;4:22.
- Callender GG, Rich TA, Perrier ND. Multiple endocrine neoplasia syndromes. *Surg Clin North Am* 2008;88:863-895.
- Field M, Shanley S, Kirk J. Inherited cancer susceptibility syndromes in paediatric practice. *J Paediatr Child Health* 2007;43:219-229.
- van Leeuwen MT, Webster AC, McCredie MR, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. *BMJ* 2010;340:c570.
- Koljonen V, Kukko H, Tukiainen E, et al. Second cancers following the diagnosis of Merkel cell carcinoma: a nationwide cohort study. *Cancer Epidemiol* 2010;34:62-65.
- Satyaprakash A, Creed R, Ravanfar P, et al. Human papillomavirus vaccines. *Dermatol Ther* 2009;22:150-157.
- Yanaoka K, Oka M, Ohata H, et al. Eradication of *Helicobacter pylori* prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. *Int J Cancer* 2009;125:2697-2703.
- Clapp RW, Jacobs MM, Loechler EL. Environmental and occupational causes of cancer: new evidence 2005-2007. *Rev Environ Health* 2008;23: 1-37.
- Liauw SL, Sylvester JE, Morris CG, et al. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. *Int J Radiat Oncol Biol Phys* 2006;66: 669-673.
- Kleinerman RA. Radiation-sensitive genetically susceptible pediatric subpopulations. *Pediatr Radiol* 2009;39:S27-S31.
- Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. *J Clin Oncol* 2005;23:2272-2279.
- Hahn H, Wojnowski L, Zimmer AM, et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. *Nat Med* 1998;4:619-622.
- Ma YP, van Leeuwen FE, Cooke R, et al. FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma. *Blood* 2012;119: 1029-1031.
- Hosking FJ, Feldman D, Bruchim R, et al. Search for inherited susceptibility to radiation-associated meningioma by genome-wide SNP linkage disequilibrium mapping. *Br J Cancer* 2011;104:1049-1054.
- Best T, Li D, Skol AD, et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. *Nat Med* 2011;17:941-943.
- Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. *J Natl Cancer Inst* 2002;94:182-192.
- Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. *J Clin Oncol* 2007;25: 1489-1497.
- Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. *Blood* 2002;100:1989-1996.
- van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. *J Clin Oncol* 2000;18:487-497.
- Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. *J Natl Cancer Inst* 1993;85:25-31.
- Hooning MJ, Aleman BM, Hauptmann M, et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. *J Clin Oncol* 2008;26:5561-5568.
- Stovall M, Smith SA, Langholz BM, et al. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. *Int J Radiat Oncol Biol Phys* 2008;72:1021-1030.

60. Behringer K, Josting A, Schiller P, et al. Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. *Ann Oncol* 2004;15:1079-1085.
61. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. *JAMA* 2003;290:465-475.
62. van Leeuwen FE, Klokmann WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. *J Natl Cancer Inst* 2003;95:971-980.
63. Inskip PD, Robison LL, Stovall M, et al. Radiation dose and breast cancer risk in the Childhood Cancer Survivor Study. *J Clin Oncol* 2009;27:3901-3907.
64. Morton LM, Gilbert ES, Hall P, et al. Risk of treatment-related esophageal cancer among breast cancer survivors. *Ann Oncol* 2012;23:3081-3091.
65. van Leeuwen FE, Klokmann WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. *J Natl Cancer Inst* 1995;87:1530-1537.
66. van den Belt-Dusebout AW, Aleman BM, Besseling G, et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. *Int J Radiat Oncol Biol Phys* 2009;75:1420-1429.
67. Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 2006;98:1528-1537.
68. Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. *N Engl J Med* 1987;317:588-593.
69. Menu-Branthomme A, Rubino C, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of soft tissue sarcoma after solid tumours during childhood. *Int J Cancer* 2004;110:87-93.
70. Rubino C, Shamsaldin A, Le MG, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. *Breast Cancer Res Treat* 2005;89:277-288.
71. Sigurdson AJ, Ronckers CM, Mertens AC, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. *Lancet* 2005;365:2014-2023.
72. Bhatti P, Veiga LH, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the Childhood Cancer Survivor Study. *Radiat Res* 2010;174:741-752.
73. Berrington de Gonzalez A, Gilbert E, Curtis R, et al. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. *Int J Radiat Oncol Biol Phys* 2013;86:224-233.
74. De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. *J Clin Oncol* 2009;27:4239-4246.
75. Franklin J, Phuetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. *Ann Oncol* 2006;17:1749-1760.
76. Deutsch M, Land SR, Begovic M, et al. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. *Cancer* 2003;98:1362-1368.
77. Zablotska LB, Neugut AL. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. *Cancer* 2003;97:1404-1411.
78. Chrouser K, Leibovich B, Bergstralh E, et al. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. *J Urol* 2008;179:S7-S11.
79. Yu CX, Amies CJ, Svatos M. Planning and delivery of intensity-modulated radiation therapy. *Med Phys* 2008;35:5233-5241.
80. Xu XG, Bednarz B, Paganetti H. A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. *Phys Med Biol* 2008;53:R193-R241.
81. Schulz RJ, Kagan AR. Should proton-beam therapy be widely adopted? *Int J Radiat Oncol Biol Phys* 2008;72:1307-1309.
82. Glimelius B, Montelius A. Proton beam therapy - do we need the randomised trials and can we do them? *Radiation Oncol* 2007;83:105-109.
83. Hall EJ. The impact of protons on the incidence of second malignancies in radiotherapy. *Technol Cancer Res Treat* 2007;6:31-34.
84. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. *Int J Radiat Oncol Biol Phys* 2006;65:1-7.
85. Flanz J, Smith A. Technology for proton therapy. *Cancer J* 2009;15:292-297.
86. Schneider U, Lomax A, Penler P, et al. The impact of IMRT and proton radiotherapy on secondary cancer incidence. *Strahlenther Onkol* 2006;182:647-652.
87. Kry SF, Salehpour M, Followill DS, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. *Int J Radiat Oncol Biol Phys* 2005;62:1195-1203.
88. Ruben JD, Davis S, Evans C, et al. The effect of intensity-modulated radiotherapy on radiation-induced second malignancies. *Int J Radiat Oncol Biol Phys* 2008;70:1530-1536.
89. Rechner LA, Howell RM, Zhang R, et al. Risk of radiogenic second cancers following volumetric modulated arc therapy and proton arc therapy for prostate cancer. *Phys Med Biol* 2012;57:7117-7132.
90. Fontenot JD, Bloch C, Followill D, et al. Estimate of the uncertainties in the relative risk of secondary malignant neoplasms following proton therapy and intensity-modulated photon therapy. *Phys Med Biol* 2010;55:6987-6998.
91. Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. *Ann Oncol* 2013;24:2113-2118.
92. Weber DC, Johanson S, Peguret N, et al. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients. *Int J Radiat Oncol Biol Phys* 2011;81:490-497.
93. Zwahlen DR, Ruben JD, Jones P, et al. Effect of intensity-modulated pelvic radiotherapy on second cancer risk in the postoperative treatment of endometrial and cervical cancer. *Int J Radiat Oncol Biol Phys* 2009;74:539-545.
94. Newhauser WD, Fontenot JD, Mahajan A, et al. The risk of developing a second cancer after receiving craniospinal proton irradiation. *Phys Med Biol* 2009;54:2277-2291.
95. Athar BS, Paganetti H. Comparison of second cancer risk due to out-of-field doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans. *Radiation Oncol* 2011;98:87-92.
96. Chung CS, Keating N, Yock T, et al. Comparative analysis of second malignancy risk in patients treated with proton therapy versus conventional photon therapy. *Int J Radiat Oncol Biol Phys* 2008;72:s8.
97. Curtis RE, Boice JD Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. *N Engl J Med* 1992;326:1745-1751.
98. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. *Blood* 1994;83:2780-2786.
99. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. *J Clin Oncol* 1994;12:1063-1073.
100. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs. Volumes 1 to 42. Supplement 7. Lyon, France: IARC; 1987.
101. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. *N Engl J Med* 1999;340:351-357.
102. Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. *J Natl Cancer Inst* 2000;92:1165-1171.
103. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. *J Clin Oncol* 1999;17:569-577.
104. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. *J Clin Oncol* 2003;21:2123-2137.
105. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. *N Engl J Med* 2005;352:1529-1538.
106. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. *J Natl Cancer Inst* 1995;87:524-530.
107. Hawkins MM, Wilson LM, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. *J Natl Cancer Inst* 1996;88:270-278.
108. Henderson TO, Oeffinger KC, Whitton J, et al. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. *Ann Intern Med* 2012;156:757-766.
109. Veiga LH, Bhatti P, Ronckers CM, et al. Chemotherapy and thyroid cancer risk: a report from the childhood cancer survivor study. *Cancer Epidemiol Biomarkers Prev* 2012;21:92-101.
110. Wilson CL, Ness KK, Neglia JP, et al. Renal carcinoma after childhood cancer: a report from the childhood cancer survivor study. *J Natl Cancer Inst* 2013;105:504-508.
111. Fung C, Fossa SD, Milano MT, et al. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. *J Clin Oncol* 2013;31:3807-3814.
112. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. *Blood* 2004;104:822-828.
113. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. *Gut* 2005;54:1121-1125.
114. Terhorst D, Drecoll U, Stockfleth E, et al. Organ transplant recipients and skin cancer: assessment of risk factors with focus on sun exposure. *Br J Dermatol* 2009;161:85-89.
115. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. *Lancet* 1999;354:34-39.
116. Hershman D, Neugut AL, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. *J Natl Cancer Inst* 2007;99:196-205.
117. Relling MV, Boyett JM, Blanco JC, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. *Blood* 2003;101:3862-3867.

118. Donadieu J, Leblanc T, Bader Meunier B, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. *Haematologica* 2005;90:45–53.
119. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. *Blood* 2006;107:4628–4635.
120. Schafhausen P, Dierlamm J, Bokemeyer C, et al. Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with imatinib. *Cancer Genet Cytogenet* 2009;189:63–67.
121. Conchon MR, Bendit I, Ferreira P, et al. Emergence of abnormal clone with monosomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors. *Int J Hematol* 2009;89:123–125.
122. Dvorak P, Hrubá M, Subrt I. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia. *Leuk Res* 2009;33:860–861.
123. Ditschkowski M, Haferlach C, Schulte C, et al. Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT. *Bone Marrow Transplant* 2009;44:265–266.
124. Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. *Blood* 2000;95:3273–3279.
125. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. *Blood* 1996;87:3633–3639.
126. Kalaycio M, Rybicki L, Pohlman B, et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. *J Clin Oncol* 2006;24:3604–3610.
127. Curtis RE, Rowings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. *N Engl J Med* 1997;336:897–904.
128. Baker KS, DeFor TE, Burns LJ, et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. *J Clin Oncol* 2003;21:1352–1358.
129. Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. *J Clin Oncol* 2005;23:2208–2214.
130. Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. *Blood* 2008;111:939–944.
131. Rizzo JD, Curtis RE, Socie C, et al. Solid cancers after allogeneic hematopoietic cell transplantation. *Blood* 2009;113:1175–1183.
132. Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. *Blood* 2011;117:316–322.
133. Limacher JM, Frebourg T, Natarajan-Ame S, et al. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. *Int J Cancer* 2001;96:238–242.
134. Alter BP. Cancer in Fanconi anemia, 1927-2001. *Cancer* 2003;97:425–440.
135. Tischkowitz M, Dokal I. Fanconi anaemia and leukaemia - clinical and molecular aspects. *Br J Haematol* 2004;126:176–191.
136. Rosenberg PS, Alter BP, Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. *Haematologica* 2008;93:511–517.
137. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. *Genes Dev* 2005;19:2925–2940.
138. Allan JM. Genetic susceptibility to radiogenic cancer in humans. *Health Phys* 2008;95:677–686.
139. Link DC, Schuettelpelz LG, Shen D, et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. *JAMA* 2011;305:1568–1576.
140. Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. *Blood* 2008;112:741–749.
141. Kalow W, Ozdemir V, Tang BK, et al. The science of pharmacological variability: an essay. *Clin Pharmacol Ther* 1999;66:445–447.
142. Evans WE, McLeod HL. Pharmacogenomics—drug disposition, drug targets, and side effects. *N Engl J Med* 2003;348:538–549.
143. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. *J Natl Cancer Inst* 2000;92:874–897.
144. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. *Cancer Epidemiol Biomarkers Prev* 2002;11:1513–1530.
145. Han FF, Guo CL, Liu LH. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. *DNA Cell Biol* 2013;32:329–335.
146. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. *Proc Natl Acad Sci U S A* 1998;95:13176–13181.
147. Bolufer P, Collado M, Barragan E, et al. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. *Br J Haematol* 2007;136:590–596.
148. Rund D, Krichevsky S, Bar-Cohen S, et al. Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. *Leukemia* 2005;19:1919–1928.
149. Guillem VM, Collado M, Terol MJ, et al. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. *Leukemia* 2007;21:1413–1422.
150. McFadyen MC, Melvin WT, Murray GI. Cytochrome P450 enzymes: novel options for cancer therapeutics. *Mol Cancer Ther* 2004;3:363–371.
151. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. *Ann Rev Pharmacol Toxicol* 2005;45:51–88.
152. Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. *Proc Natl Acad Sci U S A* 2001;98:11592–11597.
153. Fabiani E, Fianchi L, Falconi G, et al. The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes. *Leuk Lymphoma* 2014;55:1538–1543.
154. Worrillow LJ, Smith AG, Scott K, et al. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. *J Med Genet* 2008;45:142–146.
155. Worrillow LJ, Travis LB, Smith AG, et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. *Clin Cancer Res* 2003;9:3012–3020.
156. Allan JM, Smith AG, Wheatley K, et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. *Blood* 2004;104:3872–3877.
157. Seedhouse C, Bainton R, Lewis M, et al. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. *Blood* 2002;100:3761–3766.
158. Erculj N, Faganel Kotnik B, Debeljak M, et al. DNA repair polymorphisms influence the risk of second neoplasm after treatment of childhood acute lymphoblastic leukemia. *J Cancer Res Clin Oncol* 2012;138:1919–1930.
159. Seedhouse C, Faulkner R, Ashraf N, et al. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. *Clin Cancer Res* 2004;10:2675–2680.
160. Jawad M, Seedhouse CH, Russell N, et al. Polymorphisms in human hemoxybox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukemia. *Blood* 2006;108:3916–3918.
161. Rajaraman P, Bhatti P, Doody MM, et al. Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists. *Int J Cancer* 2008;123:2713–2716.
162. Li F, Sturgis EM, Zafereo ME, et al. p73 G4C14-to-A4T14 polymorphism and risk of second primary malignancy after index squamous cell carcinoma of head and neck. *Int J Cancer* 2009;125:2660–2665.
163. Collins A, Harrington V. Repair of oxidative DNA damage: assessing its contribution to cancer prevention. *Mutagenesis* 2002;17:489–493.
164. Lorenzo Y, Provencio M, Lombardia L, et al. Differential genetic and functional markers of second neoplasias in Hodgkin's disease patients. *Clin Cancer Res* 2009;15:4823–4828.
165. Karran P, Offman J, Bignami M. Human mismatch repair, drug-induced DNA damage, and secondary cancer. *Biochimie* 2003;85:1149–1160.
166. Casorelli I, Offman J, Mele L, et al. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. *DNA Repair (Amst)* 2003;2:547–559.
167. Seedhouse CH, Das-Gupta EP, Russell NH. Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. *Leukemia* 2003;17:83–88.
168. Zhu YM, Das-Gupta EP, Russell NH. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. *Blood* 1999;94:733–740.
169. Horiike S, Misawa S, Kaneko H, et al. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype. *Leukemia* 1999;13:1235–1242.
170. O'Driscoll M, Jeggo PA. The role of double-strand break repair—insights from human genetics. *Nat Rev Genet* 2006;7:45–54.
171. Baumann P, West SC. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. *Trends Biochem Sci* 1998;23:247–251.
172. Bishop DK, Ear U, Bhattacharyya A, et al. XRCC3 is required for assembly of Rad51 complexes in vivo. *J Biol Chem* 1998;273:21482–21488.
173. Liu N, Lamerdin JE, Tebbes RS, et al. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. *Molecular Cell* 1998;1:783–793.
174. Tebbes RS, Zhao Y, Tucker JD, et al. Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. *Proc Natl Acad Sci U S A* 1995;92:6354–6358.
175. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. *Cancer Res* 1998;58:604–608.
176. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. *Environ Health Perspect* 2003;111:1843–1850.

177. Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. *Carcinogenesis* 2001;22:1437–1445.
178. Brooks JD, Teraoka SN, Reiner AS, et al. Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study. *Hum Mutat* 2012;33:158–164.
179. Caldecott KW, McKeown CK, Tucker JD, et al. An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. *Mol Cell Biol* 1994;14:68–76.
180. Kubota Y, Nash RA, Klungland A, et al. Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. *EMBO J* 1996;15:6662–6670.
181. Knight JA, Skol AD, Shinde A, et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. *Blood* 2009;113:5575–5582.
182. Bhatti P, Doody MM, Rajaraman P, et al. Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists. *Radiat Res* 2010;173:214–224.
183. Funk RK, Maxwell TJ, Izumi M, et al. Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice. *Blood* 2008;112:1434–1442.
184. Cahan P, Graubert TA. Integrated genomics of susceptibility to alkylator-induced leukemia in mice. *BMC Genomics* 2010;11:638.
185. Papaemmanuil E, Hosking FJ, Vijaykrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. *Nat Genet* 2009;41:1006–1010.
186. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet* 2007;39:865–869.
187. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet* 2008;40:703–706.
188. Sadtzki S, Chetrit A, Freedman L, et al. Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. *Radiat Res* 2005;163:424–432.
189. Boulton E, Cole C, Knight A, et al. Low-penetrance genetic susceptibility and resistance loci implicated in the relative risk for radiation-induced acute myeloid leukemia in mice. *Blood* 2003;101:2349–2354.
190. Bo J, Schroder H, Kristinsson J, et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. *Cancer* 1999;86:1080–1806.
191. Relling MV, Yanishevski Y, Nemej J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. *Leukemia* 1998;12:346–352.
192. Schmiegelow K, Forestier E, Kristinsson J, et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. *Leukemia* 2009;23:557–564.
193. Stanulla M, Schaeffeler E, Moricke A, et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols. *Blood* 2009;114:1314–1318.
194. U.S. Food and Drug Administration Web site. <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=MERCAPTOPURINE>. Accessed August 22, 2014.
195. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther* 2011;89:387–391.
196. Schwab M, Schaeffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. *Pharmacogenetics* 2002;12:429–436.
197. Gurwitz D, Rodriguez-Antona C, Payne K, et al. Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. *Eur J Hum Genet* 2009;17:991–998.
198. Fargher EA, Tricker K, Newman W, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. *J Clin Pharm Ther* 2007;32:187–195.
199. Arico M, Baruchel A, Bertrand Y, et al. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29–30, 2005. *Leukemia* 2005;19:1145–1152.
200. Relling MV, Altman RB, Goetz MP, et al. Clinical implementation of pharmacogenetics: overcoming genetic exceptionalism. *Lancet Oncol* 2010;11:507–509.
201. Lennard L. Implementation of TPMT testing. *Br J Clin Pharmacol* 2014;77:704–714.
202. Chao RC, Pyzel U, Fridlyand J, et al. Therapy-induced malignant neoplasms in Nfl mutant mice. *Cancer Cell* 2005;8:337–348.
203. Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. *J Clin Oncol* 2006;24:2570–2575.
204. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. *J Med Genet* 2007;44:81–88.
205. Listernick R, Ferner RE, Liu GT, et al. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. *Ann Neurol* 2007;61:189–198.
206. Schildcrout JS, Denny JC, Bowton E, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. *Clin Pharmacol Ther* 2012;92:235–242.
207. Dolgin E. Preemptive genotyping trialed to prevent adverse drug reactions. *Nat Med* 2011;17:1323.
208. West C, Rosenstein BS. Establishment of a radiogenomics consortium. *Radiother Oncol* 2010;94:117–118.
209. Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its treatment. *J Clin Oncol* 2011;29:1885–1892.
210. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. *J Natl Cancer Inst* 2001;93:618–629.
211. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. *N Engl J Med* 1996;334:745–751.
212. Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin's disease. *J Clin Oncol* 1998;16:536–544.
213. Sankila R, Garwicz S, Olsen JH, et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. *J Clin Oncol* 1996;14:1442–1446.
214. Green DM, Hyland A, Barcos MP, et al. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. *J Clin Oncol* 2000;18:1492–1499.
215. Constine LS, Tarbell N, Hudson MM, et al. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. *Int J Radiat Oncol Biol Phys* 2008;72:24–33.
216. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. *J Clin Oncol* 2002;20:3484–3494.
217. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. *J Clin Oncol* 2000;18:498–509.
218. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. *J Clin Oncol* 2000;18:2435–2443.
219. Travis LB, Curtis RE, Glimelius B, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. *J Natl Cancer Inst* 1993;85:1932–1937.
220. Travis LB, Curtis RE, Boice JD Jr, et al. Second cancers following non-Hodgkin's lymphoma. *Cancer* 1991;67:2002–2009.
221. Brennan P, Scelo G, Hemminki K, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. *Br J Cancer* 2005;93:159–166.
222. Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. *Cancer* 2006;107:108–115.
223. Dores G, Cote T, Travis L. New malignancies following Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma. In: Curtis R, Freedman D, Ron E, et al., eds. *New Malignancies Among Cancer Survivors: SEER Cancer Registries 1973-2000* (NIH Publ No 05-0532). Bethesda, MD: National Institutes of Health; 2006:397.
224. Travis LB, Gonzalez CL, Hankey BF, et al. Hodgkin's disease following non-Hodgkin's lymphoma. *Cancer* 1992;69:2337–2342.
225. Travis LB, Curtis RE, Stovall M, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. *J Natl Cancer Inst* 1994;86:1450–1457.
226. Evans LS, Hancock BW. Non-Hodgkin lymphoma. *Lancet* 2003;362:139–146.
227. Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. *JAMA* 2001;285:1736–1745.
228. Goggins WB, Finkelstein DM, Tsao H. Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. *Cancer* 2001;91:874–880.
229. Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. *J Clin Oncol* 2010;28:4935–4944.
230. Travis LB, Curtis RE, Boice JD Jr, et al. Second malignant neoplasms among long-term survivors of ovarian cancer. *Cancer Res* 1996;56:1564–1570.
231. Aisenberg AC, Finkelstein DM, Doppke KP, et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. *Cancer* 1997;79:1203–1210.
232. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. *J Natl Cancer Inst* 2005;97:1428–1437.
233. Brennan P, Coates M, Armstrong B, et al. Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia. *Br J Cancer* 2000;82:1344–1347.
234. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. *Br J Cancer* 2001;85:997–1005.
235. Hemminki K, Lenner P, Sundquist J, et al. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. *J Clin Oncol* 2008;26:1850–1857.

236. Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. *J Clin Oncol* 2001;19:1610-1618.
237. Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. *J Clin Oncol* 2006;24:1568-1574.
238. Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. *Blood* 2004;103:1222-1228.
239. De Bruin ML, Burgers JA, Baas P, et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. *Blood* 2009;113:3679-3681.
240. Teta MJ, Lau E, Scurman BK, et al. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. *Cancer* 2007;109:1432-1438.
241. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. *J Clin Oncol* 2003;21:4386-4394.
242. Maule M, Scelo G, Pastore G, et al. Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. *J Natl Cancer Inst* 2007;99:790-800.
243. Morton LM, Dores GM, Curtis RE, et al. Stomach cancer risk after treatment for Hodgkin lymphoma. *J Clin Oncol* 2013;31:3369-3377.
244. Largent JA, Capanu M, Bernstein L, et al. Reproductive history and risk of second primary breast cancer: the WECARE study. *Cancer Epidemiol Biomarkers Prev* 2007;16:906-911.
245. Figueiredo JC, Bernstein L, Capanu M, et al. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group. *J Clin Oncol* 2008;26:1411-1418.
246. Knight JA, Bernstein L, Largent J, et al. Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: the Women's Environmental Cancer and Radiation Epidemiology Study. *Am J Epidemiol* 2009;169:962-968.
247. Li CL, Daling JR, Porter PL, et al. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. *J Clin Oncol* 2009;27:5312-5318.
248. Kirova YM, Gambotti L, De Rycke Y, et al. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. *Int J Radiat Oncol Biol Phys* 2007;68:359-363.
249. Gao X, Fisher SC, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. *Int J Radiat Oncol Biol Phys* 2003;56:1038-1045.
250. Boice JD Jr, Harvey EB, Blettner M, et al. Cancer in the contralateral breast after radiotherapy for breast cancer. *N Engl J Med* 1992;326:781-785.
251. Hill-Kayser CE, Harris EE, Hwang WT, et al. Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation. *Int J Radiat Oncol Biol Phys* 2006;66:1313-1319.
252. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005;366:2087-2106.
253. Howard RA, Gilbert ES, Chen BE, et al. Leukemia following breast cancer: an international population-based study of 376,825 women. *Breast Cancer Res Treat* 2007;105:359-368.
254. Roychoudhuri R, Evans H, Robinson D, et al. Radiation-induced malignancies following radiotherapy for breast cancer. *Br J Cancer* 2004;91:868-872.
255. Neugut AI, Ahsan H, Robinson E, et al. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. *Cancer* 1997;79:1600-1604.
256. Kaufman EL, Jacobson JS, Hershman DL, et al. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. *J Clin Oncol* 2008;26:392-398.
257. Hodgson DC, Koh ES, Tran TH, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. *Cancer* 2007;110:2576-2586.
258. Kirova YM, Vilcoq JR, Asselain B, et al. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. *Cancer* 2005;104:856-863.
259. Mery CM, George S, Bertagnolli MM, et al. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. *Cancer* 2009;115:4055-4063.
260. Magriples U, Naftolin F, Schwartz PE, et al. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. *J Clin Oncol* 1993;11:485-490.
261. Hoogendoorn WE, Hollema H, van Boven HH, et al. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. *Breast Cancer Res Treat* 2008;112:99-108.
262. Saadat M, Truong PT, Kader HA, et al. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen. *Cancer* 2007;110:31-37.
263. Bland AE, Calingaert B, Secord AA, et al. Relationship between tamoxifen use and high risk endometrial cancer histologic types. *Gynecol Oncol* 2009;112:150-154.
264. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. *J Natl Cancer Inst* 2005;97:1354-1365.
265. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. *J Clin Oncol* 2007;25:4370-4378.
266. Travis LB, Hodgson D, Allan J, et al. Second cancers. In: Devita VT, ed. *Cancer: Principles and Practice of Oncology*. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2008: 2718-2743.
267. Fossa SD, Langmark F, Aass N, et al. Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. *Br J Cancer* 1990;61:639-643.
268. Bajorin DF, Motzer RJ, Rodriguez E, et al. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. *J Natl Cancer Inst* 1993;85:60-62.
269. Boshoff C, Begent RH, Oliver RT, et al. Secondary tumours following etoposide containing therapy for germ cell cancer. *Ann Oncol* 1995;6:35-40.
270. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. *J Natl Cancer Inst* 1997;89:1429-1439.
271. Kollmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. *J Clin Oncol* 1998;16:3386-3391.
272. Fossa SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. *J Natl Cancer Inst* 2005;97:1056-1066.
273. Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. *Lancet* 1991;338:359-363.
274. Kollmannsberger C, Hartmann JT, Kanz L, et al. Therapy-related malignancies following treatment of germ cell cancer. *Int J Cancer* 1999;83:860-863.
275. Wandera EH, Fossa SD, Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. *Eur J Cancer* 1997;33:253-262.
276. Beard CJ, Travis LB, Chen MH, et al. Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. *Cancer* 2013;119:2771-2777.
277. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. *J Clin Oncol* 1993;11:415-424.
278. Christensen TB, Daugaard G, Geertsen PF, et al. Effect of chemotherapy on carcinoma in situ of the testis. *Ann Oncol* 1998;9:657-660.
279. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. *J Clin Oncol* 1999;17:1146.
280. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18. European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). *J Clin Oncol* 2005;23:1200-1208.
281. Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. *Lancet* 2005;366:293-300.
282. Wood ME, Vogel V, Ng A, et al. Second malignant neoplasms: assessment and strategies for risk reduction. *J Clin Oncol* 2012;30:3734-3745.
283. Mostofi FK. Histological change ostensibly induced by therapy in the metastasis of germ cell tumors of testis. *Prog Clin Biol Res* 1985;203:47-60.
284. Mostofi FK, Sesterhenn IA. Factors that affect the histology of metastasis of germ cell tumors of testis. *Adv Biosci* 1986;55:351-362.
285. Travis LB, Beard C, Allan JM, et al. Testicular cancer survivorship: research strategies and recommendations. *J Natl Cancer Inst* 2010;102:1114-1130.
286. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. *JAMA* 2006;296:1507-1517.
287. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. *J Clin Oncol* 2004;22:735-742.
288. Children's Oncology Group. *Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 3.0—October 2008*. <http://www.survivorshipguidelines.org/pdf/ltfuguidelines.pdf>.
289. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365:395-409.
290. Wender R, Fontham ET, Barrera E Jr, et al. American Cancer Society lung cancer screening guidelines. *CA Cancer J Clin* 2013;63:107-117.
291. Bishop JN, Harland M, Randerson-Moor J, et al. Management of familial melanoma. *Lancet Oncol* 2007;8:46-54.
292. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA* 2006;295:2727-2741.
293. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst* 2005;97:1652-1662.

294. Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors (LDTam). ClinicalTrials.gov Web site. <http://clinicaltrials.gov/show/NCT01196936>.
295. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. *J Natl Cancer Inst* 2009;101:256–266.
296. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. *Cancer Prev Res (Phila)* 2012;5:164–178.
297. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. *N Engl J Med* 1990;323:795–801.
298. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. *J Natl Cancer Inst* 2001;93:605–618.
299. Gray J, Mao JT, Szabo E, et al. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007;132:56S–68S.
300. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. *J Natl Cancer Inst* 2006;98:441–450.
301. Reulen RC, Frobisher C, Winter DL, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. *JAMA* 2011;305:2311–2319.
302. Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 2010;102:1083–1095.
303. Jenkinson HC, Hawkins MM, Stillier CA, et al. Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. *Br J Cancer* 2004;91:1905–1910.
304. Olsen JH, Moller T, Anderson H, et al. Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. *J Natl Cancer Inst* 2009;101:806–813.
305. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. *JAMA* 1997;278:1262–1267.
306. Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. *J Natl Cancer Inst* 2008;100:1771–1779.
307. Strong LC, Stine M, Norsted TL. Cancer in survivors of childhood soft tissue sarcoma and their relatives. *J Natl Cancer Inst* 1987;79:1213–1220.
308. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. *N Engl J Med* 1991;325:1330–1336.
309. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. *J Clin Oncol* 1994;12:2527–2534.
310. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. *J Natl Cancer Inst* 1996;88:183–192.
311. Cardous-Ubbink MC, Heinen RC, Bakker PJ, et al. Risk of second malignancies in long-term survivors of childhood cancer. *Eur J Cancer* 2007;43:351–362.
312. Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. *J Clin Oncol* 2009;27:2356–2362.
313. Nguyen F, Rubino C, Guerin S, et al. Risk of a second malignant neoplasm after cancer in childhood treated with radiotherapy: correlation with the integral dose restricted to the irradiated fields. *Int J Radiat Oncol Biol Phys* 2008;70:908–915.
314. Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. *Ann Intern Med* 2010;152:444–455.
315. Kenney LB, Yasui Y, Inskip PD, et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. *Ann Intern Med* 2004;141:590–597.
316. Taylor AJ, Winter DL, Stillier CA, et al. Risk of breast cancer in female survivors of childhood Hodgkin's disease in Britain: a population-based study. *Int J Cancer* 2007;120:384–391.
317. Sanna G, Lorizzo K, Rotmensz N, et al. Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors. *Ann Oncol* 2007;18:288–292.
318. Elkin EB, Klem ML, Gonzales AM, et al. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. *J Clin Oncol* 2011;29:2466–2473.
319. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 2007;57:75–89.
320. United Kingdom Children's Cancer Study Group. *Therapy-Based Long-Term Follow-Up: Practice Statement*. 2nd ed. 2005. http://www.cclg.org.uk/dynamic_files/LTFU-full.pdf.
321. Kremer LCM, Jaspers MWM, van Leeuwen FE, et al. Landelijke richtlijnen voor follow-up van overlevenden van kinderkanker. *Tijdschrift voor kindergeneeskunde* 2006;6:214–218.
322. Oeffinger KC, Ford JS, Moskowitz CS, et al. Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. *JAMA* 2009;301:404–414.
323. MacArthur AC, Spinelli JJ, Rogers PC, et al. Risk of a second malignant neoplasm among 5-year survivors of cancer in childhood and adolescence in British Columbia, Canada. *Pediatr Blood Cancer* 2007;48:453–459.
324. Taylor AJ, Croft AP, Palace AM, et al. Risk of thyroid cancer in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. *Int J Cancer* 2009;125:2400–2405.
325. Acharya S, Sarafoglou K, LaQuaglia M, et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. *Cancer* 2003;97:2397–2403.
326. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 2008;100:1368–1379.
327. Veiga LH, Lubin JH, Anderson H, et al. A pooled analysis of thyroid cancer incidence following radiotherapy for childhood cancer. *Radiat Res* 2012;178:365–376.
328. Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. *J Clin Oncol* 2004;22:4541–4550.
329. O'Brien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. *J Clin Oncol* 2010;28:1232–1239.
330. Le Vu B, de Vathaire F, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. *Int J Cancer* 1998;77:370–377.
331. Henderson TO, Whitton J, Stovall M, et al. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 2007;99:300–308.
332. Kalra S, Grimer RJ, Spooner D, et al. Radiation-induced sarcomas of bone: factors that affect outcome. *J Bone Joint Surg Br* 2007;89:808–813.
333. Bowers DC, Nathan PC, Constine L, et al. Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review. *Lancet Oncol* 2013;14:e321–e328.
334. Taylor AJ, Frobisher C, Ellison DW, et al. Survival after second primary neoplasms of the brain or spinal cord in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. *J Clin Oncol* 2009;27:5781–5787.
335. Taylor AJ, Little MP, Winter DL, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. *J Clin Oncol* 2010;28:5287–5293.
336. Flint-Richter P, Sadetzki S. Genetic predisposition for the development of radiation-associated meningioma: an epidemiological study. *Lancet Oncol* 2007;8:403–410.
337. Braam KI, Overbeek A, Kaspers GJ, et al. Malignant melanoma as second malignant neoplasm in long-term childhood cancer survivors: a systematic review. *Pediatr Blood Cancer* 2012;58:665–674.
338. Perkins JL, Liu Y, Mitby PA, et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2005;23:3733–3741.
339. Leisenring W, Friedman DL, Flowers ME, et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. *J Clin Oncol* 2006;24:1119–1126.
340. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2006;24:476–483.
341. Overbeek A, van den Berg MH, Kremer LC, et al. A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges. *BMC Cancer* 2012;12:363.
342. Tukenova M, Diallo I, Anderson H, et al. Second malignant neoplasms in digestive organs after childhood cancer: a cohort-nested case-control study. *Int J Radiat Oncol Biol Phys* 2012;82:e383–e390.
343. Nottage K, McFarlane J, Krasin MJ, et al. Secondary colorectal carcinoma after childhood cancer. *J Clin Oncol* 2012;30:2552–2558.
344. Cure Search for Children's Cancer. National Childhood Cancer Foundation Web site. <http://www.curesearch.org/>.
345. Nathan PC, Ness KK, Mahoney MC, et al. Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *Ann Intern Med* 2010;153:442–451.
346. Boukheris H, Stovall M, Gilbert ES, et al. Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. *Int J Radiat Oncol Biol Phys* 2013;85:776–783.
347. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature* 1986;323:643–646.
348. Maccarthy A, Bayne AM, Brownbill PA, et al. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951–2004. *Br J Cancer* 2013;108:2455–2463.
349. Marees T, van Leeuwen FE, de Boer MR, et al. Cancer mortality in long-term survivors of retinoblastoma. *Eur J Cancer* 2009;45:3245–3253.
350. Yu CL, Tucker MA, Abramson DH, et al. Cause-specific mortality in long-term survivors of retinoblastoma. *J Natl Cancer Inst* 2009;101:581–591.
351. Abramson DH, Melson MR, Dunkel IJ, et al. Third (fourth and fifth) non-ocular tumors in survivors of retinoblastoma. *Ophthalmology* 2001;108:1868–1876.
352. Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. *J Natl Cancer Inst* 2007;99:24–31.

353. Francis JH, Kleinerman RA, Seddon JM, et al. Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma. *Gynecol Oncol* 2012;124:254–259.
354. Ginsberg JP, Goodman P, Leisenring W, et al. Long-term survivors of childhood Ewing sarcoma: report from the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 2010;102:1272–1283.
355. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? *Ann Intern Med* 1969;71:747–752.
356. Elena JW, Travis LB, Simonds NI, et al. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. *J Natl Cancer Inst* 2013;105:85–94.
357. Travis LB, Bhatia S, Allan JM, et al. Second primary cancers. In: Devita VT, Lawrence TS, Rosenberg SA, eds. *Cancer: Principles and Practice of Oncology*. 9th ed. Philadelphia: Lippincott Williams and Wilkins; 2011.
358. Wheeler HE, Maitland ML, Dolan ME, et al. Cancer pharmacogenomics: strategies and challenges. *Nat Rev Genet* 2013;14:23–24.
359. Freedman AN, Sansbury LB, Figg WD, et al. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. *J Natl Cancer Inst* 2010;102:1698–1705.
360. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, LIVESTRONG Young Adult Alliance. *Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer. Report of the Adolescent and Young Adult Oncology Progress Review Group*. Bethesda, MD: NIH; 2006.
361. Choi G, Huang B, Pinarbasi E, et al. Genetically mediated NF1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms. *Cancer Res* 2012;72:6425–6434.
362. Freedman AN, Seminara D, Gail MH, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. *J Natl Cancer Inst* 2005;97:715–723.
363. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. *CA Cancer J Clin* 2012;62:243–274.
364. World Cancer Research Fund, American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. <http://www.dietandcancerreport.org/?p=er&JServSessionIdr010=xaogdintz2.app43a>.
365. Landier W, Armenian SH, Lee J, et al. Yield of screening for long-term complications using the Children's Oncology Group long-term follow-up guidelines. *J Clin Oncol* 2012;30:4401–4408.